Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) saw a significant growth in short interest in the month of May. As of May 29th, there was short interest totaling 40,237 shares, a growth of 83.8% from the May 14th total of 21,893 shares. Based on an average trading volume of 4,758 shares, the short-interest ratio is presently 8.5 days.
Relief Therapeutics Stock Performance
OTCMKTS:RLFTF remained flat at $0.33 on Tuesday. The company’s stock had a trading volume of 10,542 shares, compared to its average volume of 3,373. Relief Therapeutics has a fifty-two week low of $0.32 and a fifty-two week high of $4.88. The business has a 50-day moving average price of $0.45 and a 200-day moving average price of $1.31.
About Relief Therapeutics
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
Featured Articles
- Five stocks we like better than Relief Therapeutics
- Goldman’s S&P 500 Target Looks More Reachable After the Latest Rally
- 3 Stocks Diluting Shareholders to Fund Big Long-Term Opportunities
- Father’s Day Investing: 3 Stocks Built for Long-Term Returns
- This Golden Cross Could Send Urban Outfitters to New Highs
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
